Bulletin from the extraordinary general meeting in CELLINK AB (publ)

At the extraordinary general meeting in CELLINK AB (publ), held on September 11, 2020, the following resolution was passed.

  • The extraordinary general meeting resolved to approve the board of directors’ resolution on a directed share issue of not more than 1,625,000 B-shares, entailing an increase in the share capital of not more than SEK 40,625. The shares have, with deviation from the shareholder’s pre-emption rights, been allotted to Carnegie Investment Bank AB (publ) on behalf of a Swedish institutional investor approached in advance. The subscription price at the time of the board of directors’ resolution amounted to SEK 160 per share and was established through negotiations with certain institutional investors and is considered to constitute a fair market price. The reasons for the deviation from the shareholders’ pre-emption rights are that it is considered beneficial for CELLINK and its shareholders to broaden the shareholder base and to take advantage of the opportunity to raise capital on favorable terms for the company.

Approximately 67 per cent of the votes were represented at the extraordinary general meeting.

For further information, please contact:

Erik Gatenholm, CEO                                                            Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00                                       Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566                                             Phone (US): +1 (857) 332 2138

Email: [email protected]                                                           Email: [email protected]

The information was submitted for publication, through the agency of the contact persons set out above, on September 11, 2020 at 5:45 p.m. (CEST).

About CELLINK

CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.

Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

Senaste pressreleaserna
March 22, 2020RegulatoryUppdatering avseende COVID-19
November 18, 2019RegulatoryKallelse till årsstämma i CELLINK AB